CA Patent

CA3055019A1 — Manufacture of a crystalline pharmaceutical product

Assigned to Orion Oyj · Expires 2018-09-13 · 8y expired

What this patent protects

The present invention relates to crystalline particles of a compound (I) which is a N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1- hydroxyethyl)-1H-pyrazole-3-carboxamide having specific surface area (SSA) in the range from 8 to 16 m2/g, wherein the spec…

USPTO Abstract

The present invention relates to crystalline particles of a compound (I) which is a N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1- hydroxyethyl)-1H-pyrazole-3-carboxamide having specific surface area (SSA) in the range from 8 to 16 m2/g, wherein the specific surface area (SSA) is analyzed using the three-point nitrogen adsorption technique based on the Brunauer, Emmett and Teller (BET) theory. Also, the invention relates to a dosage forms of said crystalline particles and a method for the preparation of said particles. The compound (I) is a potent androgen receptor (AR) modulator which is useful as a medicament for example in the treatment of prostate cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA3055019A1
Jurisdiction
CA
Classification
—
Expires
2018-09-13
Drug substance claim
No
Drug product claim
No
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.